US Stock Movement | Zai Lab (ZLAB.US) Rises Over 8% as DLL3 ADC Launches Global Phase III Clinical Trial for First-Line SCLC

智通财经APP has learned that on Wednesday, Zai Lab (ZLAB.US) rose over 8% to $27.44. In the news, on August 31, Zai Lab registered a global phase III clinical trial of ZL-1310 combined with PD-L1 antibody as a first-line treatment for ES-SCLC on Clinicaltrials.gov. This global phase III trial plans to enroll 530 first-line ES-SCLC patients and is expected to be preliminarily completed in June 2030.